ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2111

An International Patient Survey to Identify Candidate Items for Classifying Early-Stage Symptomatic Knee Osteoarthritis

Lauren King1, Armaghan Mahmoudian2, Jean Liew3, Quike Wang4, Ian Stanaitis5, Dieuwke Schiphof6, Leigh Callahan7, David Hunter8, Tom Appleton9, Aleksandra Turkiewicz10, Martin Englund11, Stefan Lohmander11, Ida Kristin Haugen12, Tuhina Neogi13, Gillian Hawker1 and Jos Runhaar6, and OARSI Early-stage Symptomatic Knee Osteoarthritis Initiative, 1University of Toronto, Toronto, ON, Canada, 2University of West Florida, Pensacola, FL, 3Boston University, Boston, MA, 4Shanghai Sixth People's Hospital, Shanghai, China (People's Republic), 5Women's College Hospital, Toronto, ON, Canada, 6Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 7University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, 8Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 9The University of Western Ontario, London, ON, Canada, 10,Lund University, Lund, Sweden, 11Lund University, Lund, Sweden, 12Diakonhjemmet Hospital, Oslo, Norway, 13Boston University Chobanian & Avedisian School of Medicine, Boston, MA

Meeting: ACR Convergence 2024

Keywords: classification criteria, Osteoarthritis, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Osteoarthritis – Clinical Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Osteoarthritis Research Society International (OARSI) has launched an initiative to develop classification criteria for early-stage symptomatic knee osteoarthritis (EsSKOA). The goal is to establish a standardized way to identify and enrol individuals with symptomatic knee OA into clinical studies at an earlier stage of disease. To incorporate patient perspectives into the first phase (item generation), our objectives were to 1) develop a list of symptoms which, according to individuals living with knee OA, emerged within the first year of symptom onset; and 2) identify symptoms, signs and/or tests perceived to have helped them and their health professional(s) indicate their symptoms were due to knee OA and not another condition.

Methods: We conducted an international cross-sectional survey of people living with knee OA. We recruited participants from Australia, Canada, Netherlands, and USA. Included participants had to self-report a health-professional diagnosis of knee OA or be ≥45 years old, report activity-related knee pain, and indicate the ability to recall their earliest knee symptoms (within the first year from symptom onset). Participants completed an online questionnaire which asked if they experienced changes to how their knee looked, felt, moved, and overall wellbeing within the first year of knee symptom onset (5-point Likert from “definitely experienced” to “definitely did not experience”), and if experienced changes, describe specific symptoms using free-text. Participants were asked about specific symptoms, signs and/or tests that they perceived helped them and their health professional to know they had OA and not another condition. For quantitative data, we calculated the number and proportions or median and interquartile range, as appropriate. Analysis of free-text data was informed by conventional content analysis.

Results: We included 92 participants; mean age 68 years, 69% were women, 91% reported health-professional diagnosis of knee OA, and 27% reported onset of knee OA symptoms within the prior 5 years (Table 1). Within the first year of experiencing knee symptoms, the majority of participants “definitely” or “probably” experienced a change in how their knee looked (68%), felt (86%), moved (60%), or in overall wellbeing (55%). Specific symptoms within the first year described by >10% of participants are shown in Table 2. Only 35% of participants reported they sought care from a health professional within the first year of experiencing symptoms. Symptoms, signs and/or tests that participants indicated helped to determine they had knee OA and not another cause for knee symptoms, including clinical history (14%), physical exam (17%), and radiographs or other imaging (51%).

Conclusion: This international survey identified symptoms experienced by people living with knee OA within the first year of their illness. Given that few individuals seek healthcare within the first year, these provide key perspectives on the OA illness. The results of this study will be combined with those of a Delphi exercise with OA health professionals to generate a comprehensive list of items to be considered in subsequent phases of this initiative.

Supporting image 1

Supporting image 2


Disclosures: L. King: None; A. Mahmoudian: None; J. Liew: None; Q. Wang: None; I. Stanaitis: None; D. Schiphof: None; L. Callahan: None; D. Hunter: Novartis, 2, TLC, 2; T. Appleton: AbbVie/Abbott, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 6, Servier, 5; A. Turkiewicz: None; M. Englund: Cellcolabs AB, 2, Grünenthal Sweden AB, 2, Key2Compliance AB, 2; S. Lohmander: Arthro Therapeutics, 2, Rho inc., 1; I. Haugen: AbbVie/Abbott, 2, GlaxoSmithKlein(GSK), 2, Grünenthal, 2, Novartis, 2, Pfizer/Lily, 5; T. Neogi: Amgen, 2, Eli Lilly, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2, Sobi, 2; G. Hawker: None; J. Runhaar: None.

To cite this abstract in AMA style:

King L, Mahmoudian A, Liew J, Wang Q, Stanaitis I, Schiphof D, Callahan L, Hunter D, Appleton T, Turkiewicz A, Englund M, Lohmander S, Haugen I, Neogi T, Hawker G, Runhaar J. An International Patient Survey to Identify Candidate Items for Classifying Early-Stage Symptomatic Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/an-international-patient-survey-to-identify-candidate-items-for-classifying-early-stage-symptomatic-knee-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-international-patient-survey-to-identify-candidate-items-for-classifying-early-stage-symptomatic-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology